The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...

Health-care companies fell as a lackluster earnings season for the sector wound down. Shares of vaccine maker Moderna fell after it warned it expects to report a hefty quarterly loss, as recapturing ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

We recently compiled a list of the 10 Firms Fall Amid Disappointing Earnings Performance. In this article, we are going to ...

It has been almost five years since the COVID-19 pandemic happened and close to two years since President Marcos lifted the public health emergency in the country. And yet, costly irregularities, ...

Shares of vaccine makers and packaged food companies fell on Tuesday after President Donald Trump's pick for U.S. health ...

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.